Fablyn
Generic name: lasofoxifene tartrate
Treatment for: Osteoporosis
Pfizer Statement on Lasofoxifene
NEW YORK, September 13, 2005 -- Pfizer Inc said today it has received a non-approvable letter from the U.S. Food and Drug Administration regarding lasofoxifene (Oporia), a selective estrogen receptor modulator for the prevention of osteoporosis.
Pfizer said that it will be reviewing its submission with the FDA and considering various possible courses of action.
Source: Pfizer Inc
Posted: September 2005
Related articles
- Ligand Signs License Agreement with Ethicor for Oral Lasofoxifene - July 24, 2013
- Pfizer Receives FDA Complete Response Letter for Lasofoxifene - January 20, 2009
- Ligand Partner Pfizer Submits NDA for Fablyn - January 16, 2008
Fablyn (lasofoxifene tartrate) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
